Hemophilia Therapeutics Market

Hemophilia is a rare, inherited disorder in which blood doesn?t clot normally due to the lack of sufficient blood clotting factor. Clotting factor is a protein required for blood clotting to occur normally. These proteins work with platelets i.e. small blood cell fragments that form in the bone marrow, to help the blood clot. Hemophilia is passed from parents to children through genes.
Hemophilia Therapeutics Market contains market size and forecasts of Hemophilia Therapeutics in Global, including the following market information:
Global Hemophilia Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hemophilia Therapeutics market was valued at 9756 million in 2021 and is projected to reach US$ 13580 million by 2028, at a CAGR of 4.8% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Hemophilia A Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hemophilia Therapeutics include Bayer AG, Pfizer, Inc., Novo Nordisk A/S, Baxter International Inc., Biogen Idec, Inc., Genetics Institute, Alpha Therapeutics Corporation, Expression Therapeutics and Swedish Orphan Biovitrum AB.. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Hemophilia Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hemophilia Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hemophilia Therapeutics Market Segment Percentages, by Type, 2021 (%)
Hemophilia A
Hemophilia B
Hemophilia C
Global Hemophilia Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Hemophilia Therapeutics Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Ambulatory Surgical Centers
Global Hemophilia Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hemophilia Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hemophilia Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hemophilia Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer AG
Pfizer, Inc.
Novo Nordisk A/S
Baxter International Inc.
Biogen Idec, Inc.
Genetics Institute
Alpha Therapeutics Corporation
Expression Therapeutics
Swedish Orphan Biovitrum AB.